There is considerable evidence that stress-related psychiatric disorders, including depression and post-traumatic stress disorder (PTSD), are associated with hypersecretion of corticotropin-releasing factor (CRF) within the central nervous system (CNS). One line of evidence that is consistent with central CRF hypersecretion in these disorders is the blunted adrenocorticotropin hormone (ACTH) response to intravenous CRF administration, likely a consequence, at least in part, of downregulation of anterior pituitary CRF receptors. The present study tests the hypothesis that elevated cerebrospinal fluid (CSF) concentrations of CRF and a secondary ACTH secretagogue, arginine vasopressin (AVP), are associated with diminished adenohypophyseal responses in a standard CRF stimulation test. CSF concentrations of CRF and AVP, and plasma ACTH responses to the administration of 1 mg/kg ovine CRF (oCRF) were measured in healthy adult women with and without current major depression and/or a history of significant childhood abuse. The primary outcome measure was ACTH area under the curve (AUC) in the CRF stimulation test. Multiple linear regression was performed to identify the impact of CSF CRF and AVP concentrations upon the pituitary response to CRF stimulation. The regression model explained 56.5% of the variation in the ACTH response to CRF stimulation. The relationship of CSF concentrations of CRF to ACTH responses to CRF were best described by a third-order function that was inversely correlated over most of the range of studied values. The association of ACTH response with CSF concentration of AVP and the dose of oCRF followed second-order kinetics. These findings support the hypothesis that central CRF hypersecretion is associated with a blunted ACTH response to exogenously administered CRF, explaining almost 60% of the variation in the ACTH response to CRF.
INTRODUCTION
Considerable evidence has accrued over the last three decades implicating corticotropin-releasing factor (CRF) as the preeminent regulator of the mammalian response to stress (cf Newport and Nemeroff, 2001 for a review). Indeed, dysfunction in CRF neuronal systems is believed to be critical to the etiopathogenesis of numerous stress-related disorders including major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (Nemeroff, 1996; Keck and Holsboer, 2001) . In support of this hypothesis, standard hypothalamic-pituitary-adrenal (HPA) axis challenge tests, such as the CRF stimulation test, have been utilized as peripheral 'neuroendocrine windows' (Plotsky et al, 1998) to surmise the activity of hypothalamic CRF neuronal systems.
A blunted adrenocorticotropin hormone (ACTH) response in the CRF stimulation test has repeatedly been reported in patients with MDD Holsboer et al, 1987; Amsterdam et al, 1988; Kathol et al, 1989; Heim et al, 2001) and PTSD (Smith et al, 1989; Young et al, 1990; Heim et al, 1997 Heim et al, , 2001 . It has been suggested that this diminished ACTH response to exogenous CRF is a consequence of chronic hyperactivity of CRF-secreting neurons in the hypothalamic paraventricular nucleus that induces a downregulation of CRF receptors at the adenhohypophysis. In addition, hypothalamic secretion of arginine vasopressin (AVP), an important co-secretagogue of pituitary ACTH, may likewise influence patterns of pituitary response to CRF stimulation (Scott and Dinan, 1998) . Despite the hypothesis that the blunted ACTH response in the CRF stimulation test is a result of central CRF hypersecretion, this hypothesis has never been formally tested in a clinical sample. The aim of the present study was to test the hypothesis that central hypersecretion of CRF, and possibly AVP, is associated with diminished ACTH responsivity in the CRF stimulation test.
METHOD Participants
The study sample was comprised of a heterogeneous assortment of adult women: with or without a history of significant childhood sexual or physical abuse, and with or without current MDD or PTSD. This diverse sample was collected in an effort to delineate the association between the candidate predictor variables and the primary outcome variable over the range of HPA axis activity commonly observed in healthy volunteers and those with psychiatric illness. All women were in their reproductive years and reported regular menstrual cycles. General exclusion criteria were pregnancy or lactation, significant medical illness, any history of psychotic symptoms or bipolar disorder, active substance use disorder or eating disorder within 6 months, or current treatment with psychotropic or hormonal medications (except oral contraceptives). All subjects were recruited from responses to newspaper advertising and were remunerated for participation. After a complete description of the study to the subjects, written informed consent was obtained. The Emory University School of Medicine Institutional Review Board approved the study protocol.
Clinical Procedures
Psychometric evaluation included the Structured Clinical Interview for DSM-IV (SCID) (First et al, 1997) for the diagnosis of MDD, PTSD, and other psychiatric disorders. In addition, the semistructured early trauma inventory (ETI) was utilized to assess the presence and severity of childhood trauma, including physical, sexual, and emotional child abuse or neglect (Bremner et al, 2000) .
Participants were admitted at 10:00 am to the NIH-funded General Clinical Research Center at Emory University Hospital and remained at bed rest with no oral intake except water beginning 2 h before and throughout all test procedures. On day 1 of hospitalization, an experienced faculty member of the Department of Anesthesiology at Emory University performed lumbar puncture at 4:00 pm using standard aseptic technique. A 4-6 ml cerebrospinal fluid (CSF) sample was collected, transferred to coded 1 ml aliquot tubes, and stored at À801C until assay.
The CRF stimulation test was performed on day 2 of hospitalization. An intravenous catheter was inserted into a forearm vein at 12:00 pm, and patency was maintained by slow saline infusion. Venous blood samples were collected at 30-min intervals from 1:30 until 4:00 pm to obtain baseline hormonal measures. At 4:00 pm, 1 mg/kg ovine CRF (oCRF) was administered through the intravenous catheter. Venous blood samples were collected at 5, 15, 30, 60, 90 , and 120 min after oCRF administration. All blood samples were collected in chilled EDTA-containing tubes, placed immediately on ice, and centrifuged at 41C for 10 min at 3000 rpm. Plasma was separated, coded, and stored at À801C until assay.
Laboratory Assays
Laboratory personnel masked to subject demographics and sample sequence conducted all neuroendocrine assays. Concentrations of CSF CRF were measured in duplicate 450-ml aliquots that were lyophilized, reconstituted in 200 ml assay buffer, and incubated at 41C for 18 h with 100 ml antiserum (oC33) raised in rabbits against oCRF at a final dilution of 1 : 21 875 in assay buffer containing 1% normal rabbit serum. Radiolabeled [
125 I]Tyr 0 -rat/human CRF (20 000 cpm in 50 ml buffer) was then added to each tube. After incubation for 24 h at 41C, 10 ml goat anti-rabbit serum was added to precipitate bound CRF. The standards containing 450 ml artificial CSF and 0.625-640 pg CRF/tube were prepared using rat/human CRF and were treated identically as the human CSF samples. The sensitivity of the assay was 1.25 pg/tube, with 50% displacement of radiolabeled CRF (IC 50 ) at 30 pg/tube. The inter-and intra-assay coefficients of variation have been measured every 6 months for the past 15 years with a set of identical samples (pooled human CSF) in two separate assays. The difference between these values has ranged from 10 to 13% for interassay measurements and from 2 to 6% for intra-assay measurements over this period of time.
The AVP assay utilized synthetic standard material (Arg 8 -Vasopressin: Bachem, Torrance, CA). Iodinated vasopressin was prepared in our laboratory via Chloramine T oxidation and high-pressure liquid chromatography (HPLC) purification. Standard curves were prepared in artificial CSF, and two CSF pools were used as quality control preparations. Prior to assay, standards, controls, and samples were extracted on C-18 Sep Paks (Waters, Milford, MA). The extracts were then concentrated by lyophilization and reconstituted in assay buffer. They were subsequently incubated with the primary antisera at 41C for 24 h. After addition of the tracer, the extracts were incubated for an additional 24 h. A second antibody, goat anti-rabbit gamma globulin, was then added with a 1 : 5 dilution of normal rabbit serum to induce precipitation, and the incubation continued for an additional 3 h. After separating the bound component by centrifugation, the tubes were decanted and counted in a gamma counter. The working sensitivity of the assay is 0.3 pg/ml. The intra-and interassay coefficients of variation were 5 and 9%, respectively.
Plasma samples from the CRF stimulation test were assayed for ACTH and cortisol concentrations using sensitive commercial radioimmunoassays (ACTH: Nichols, San Juan Capistrano, CA; cortisol: DiaSorin, Stillwater, MN). The intra-and interassay coefficients of variation were 4.5 and 6.3%, respectively, for ACTH, and 3.8 and 7.3%, respectively, for cortisol. Assay sensitivities were 0.5 pg/ml for ACTH and 0.18 mg/dl for cortisol.
Statistical Analysis
Descriptive analysis of demographic and clinical data was conducted using frequency tests for categorical and ordinal data, and calculation of sample means and standard deviations for continuous data. A multiple regression analysis was then performed with assumptions of normality, linearity, and homoscedasticity between predicted outcome variable values and errors of prediction (Kleinbaum et al, 1998) . The primary outcome variable, ACTH area under the curve (ACTH AUC ) after oCRF administration, was calculated relative to baseline plasma ACTH concentration using the trapezoidal rule. Since the initial descriptive analysis revealed the distribution of ACTH AUC measures to be positively skewed, the dependent variable was normalized via logarithmic transformation. The Shapiro-Wilks test (Shapiro and Wilks, 1965) , an appropriate test of normality for small sample sizes (Kleinbaum et al, 1998) , demonstrated that post-transformation residuals were normally distributed (w ¼ 0.9791, p ¼ 0.6575).
For the establishment of a stable regression model, four candidate predictor variables were identified: CRF concentration in cerebrospinal fluid (CRF CSF ), AVP concentration in cerebrospinal fluid (AVP CSF ), baseline plasma cortisol concentration (CORT PLASMA ) immediately prior to administration of oCRF, and dose of oCRF administered (oCRF DOSE ). CORT PLASMA was included in the model as a crude index of glucocorticoid feedback activity within the HPA axis. Although the oCRF DOSE utilized in the study was body weight-adjusted in an effort to standardize HPA axis stimulation, we were uncertain as to whether this modification would produce proportional results over the range of body weights of the study participants. Consequently, oCRF DOSE was also included as a candidate predictor in the model. Since the kinetics of HPA axis activity are poorly understood, and because numerous studies indicate that various aspects of HPA axis function may best fit quadratic or higher-order polynomial functions (Hanada et al, 1985; Kemppainen et al, 1986; Dellwo and Beauchene, 1990; Coppinger et al, 1991; Kosowska, 1992; Apple et al, 1993; Kling et al, 1993) , we included squared and cubed polynomials of each candidate predictor in addition to product interaction terms between each of the primary predictors in the model. To eliminate the inherent tendency for multicollinearity in polynomial models, each of the candidate predictor variables was converted to an orthogonal polynomial. A backward elimination procedure with a ¼ 0.10 for retention was used to determine the predictor variables in the final model. A candidate predictor was retained if a higher-order polynomial of the variable or a product interaction term containing the variable was statistically significant. The condition number (CN ¼ 8.03) of the final model indicates that there is little potential for significant collinearity. A stable estimate of parameters in the regression analysis can therefore be assumed.
Since oral contraceptives have been associated with altered HPA axis measures including lower concentrations of ACTH (Carr et al, 1979; Nickelsen et al, 1989) , elevated concentrations of cortisol (Carr et al, 1979; Nickelsen et al, 1989; Meulenberg and Hofman, 1990 ) and cortisol binding globulin (Bulbrook et al, 1973; Carr et al, 1979; Carol et al, 1980; Fujimoto et al, 1986; Kirschbaum et al, 1999) , and diminished salivary cortisol responses to various stressors (Kirschbaum et al, 1995 (Kirschbaum et al, , 1996 (Kirschbaum et al, , 1996 , the holdout sample approach (Kleinbaum et al, 1998 ) was used to assess the impact of oral contraceptive use upon the reliability of the model. To implement this approach, a second regression analysis was performed using the same dependent variable and predictor variables against the holdout sample of participants who were not taking oral contraceptives. Shrinkage on cross-validation was then calculated by subtracting the squared correlation (R 2 ) of the predicted vs observed outcome values in the model of the full sample from the squared correlation (R 2 ) of the predicted vs observed outcome values in the model of the holdout sample. A shrinkage of less than 10% (Kleinbaum et al, 1998) was determined a priori as the threshold to indicate whether oral contraceptive use compromised the reliability of the regression model.
RESULTS

Descriptive Data
A total of 47 subjects were enrolled and completed all aspects of the study. Of these 47 enrolled patients, two were excluded because there was an insufficient CSF volume to assay both CRF and AVP, four were excluded due to missing data in the CRF stimulation test, and one was excluded due to outlying values in the CRF stimulation test (ie ACTH concentrations after oCRF administration were lower than baseline ACTH concentrations, indicating a probable procedural error in conducting the test). Table 1 presents a descriptive summary of the demographic and clinical characteristics of the remaining 40 participants. Of note, the study participants were evenly distributed between those with a history of child abuse (n ¼ 21, 52.5%) and those with no history of child abuse (n ¼ 19, 48.5%). Similarly, approximately one-half had no current psychiatric illness (n ¼ 18, 45%) while the remainder (n ¼ 22, 55%) fulfilled DSM-IV criteria for MDD, PTSD, or both. None of the study participants were receiving any psychotropic medications, and only three of the 40 subjects had discontinued any psychopharmacological agent in order to participate. In those subjects, psychotropic medicines were discontinued a minimum of 2 weeks prior to initiation of any study procedures (6 weeks earlier for fluoxetine). Seven of the 40 subjects were receiving oral contraceptives during the study. Table 2 presents the mean and standard deviation of the dependent variable (ACTH AUC ) and each of the candidate predictor variables.
Multiple Regression Analysis
The results of the multiple regression analysis are presented in Table 3 and Figure 1 . As anticipated, the correlation of the predictor variables with ACTH AUC was predicted by polynomial rather than simple linear functions. As a whole, the linear, quadratic, and cubic functions of CRF CSF explained 22.8% of the variability in ACTH AUC (F ¼ 6.04, df ¼ 3, p ¼ 0.0023 The regression model constructed from the holdout sample of those subjects who were not receiving oral contraceptives (n ¼ 33) was also highly significant (F ¼ 4.31, df ¼ 8, p ¼ 0.0025). The shrinkage on cross-validation between the full sample and the holdout sample was only 1.42%, indicating that the reliability of the model was not impacted by oral contraceptive use.
DISCUSSION
Clinical research often relies upon minimally invasive, peripheral measures to provide a 'neuroendocrine window' for drawing conclusions regarding brain function and dysfunction. It is imperative, therefore, that the interpretations derived from these peripheral indices be subjected to confirmation whenever possible. Animal models utilizing invasive techniques that can rarely be implemented in human subjects are often used in this confirmatory manner. For example, a recent rodent study confirmed the hypothesis that diminished CRF receptor binding in the anterior pituitary is associated with a blunted ACTH response to CRF stimulation (Hauger et al, 2002) . Preclinical data is certainly informative; however, its utility is limited by the incomplete homology of any animal model for the human condition (Newport et al, 2002) .
The key finding in this study is the confirmation that the CSF concentration of CRF is inversely correlated with pituitary responsiveness to CRF as evidenced by ACTH AUC during the CRF stimulation test. Although the model depicts a complex association following third-order kinetics that is further obscured by the interaction of CRF with AVP, ACTH responses are generally diminished as CRF CSF rises across the range of studied values. This finding notably lends credence to the common inference that blunted ACTH responses to CRF stimulation are a consequence of chronic CRF hypersecretion.
The association between CRF CSF and ACTH AUC appears to contradict the widespread conviction that CSF CRF collected by lumbar puncture principally originates from extra-hypothalamic sources. Whereas it is generally accepted that pituitary ACTH secretion is stimulated by CRF secreted by neurons emanating from the parvocellular nucleus of the hypothalamus (Lennard et al, 1993) , the absence of a correlation between the diurnal cycles of CSF CRF and plasma cortisol concentrations (Garrick et al, 1987; Kalin et al, 1987; Geracioti et al, 1997; Kling et al, 1994 ) is believed to indicate that most CSF CRF does not originate from the hypothalamus. Given the lengthy transit flow time of CSF through the central nervous system (CNS), the 10-min half-life of CRF within CSF suggests that a preponderance of the CRF present in lumbar CSF is secreted by the spinal cord (Geracioti et al, 1997) . This is consistent with evidence of a craniocaudal CRF gradient in the CSF of suicide victims (Arato et al, 1989) .
Lumbar CRF studies may nevertheless be a reliable index of CRF neuronal function at higher centers within the CNS. For example, CRF concentrations in lumbar CSF were highly correlated to those in cisternal CSF (Geracioti et al, 1997) . Furthermore, because active transport mechanisms may exist to rapidly clear CRF and other neuropeptides from the cerebral ventricles to lower regions of the CNS (Oldfield et al, 1985) , analyses based upon CSF bulk flow rates may underestimate the contribution of higher CNS centers to the CRF present in lumbar CSF. Such mechanisms may underlie the numerous reports of elevated CSF CRF concentrations in patients with stress-related psychiatric disorders (cf Newport and Nemeroff, 2001 for a review) and the association of higher CSF CRF concentrations with brain activation patterns in experimental animals that accompany fearful temperament (Kalin et al, 2000) . Preclinical evidence indicates that CSF CRF may also be more directly related to HPA axis activity than anticipated. Intraventricular administration of CRF in a primate model was found to stimulate HPA axis activation (Rock et al, 1984) , and bilateral ablation of the parvocellular nuclei was observed to reduce CSF CRF concentrations by 50% in a rodent study (Hong et al, 1995) . Although the dissociation between the circadian rhythms of CSF CRF and plasma glucocorticoids (Garrick et al, 1987; Kalin et al, 1987; Geracioti et al, 1997; Kling et al, 1994) suggests that reliable estimates of the short-term relationship between CSF CRF concentrations and HPA axis activity may be difficult, if not impossible, to obtain, the current study sought to delineate not the acute association but the long-term relationship between CSF CRF concentrations and HPA axis responsivity. Even if CSF CRF primarily originates from extrahypothalamic sources, the inverse relationship between CSF CRF concentrations and pituitary responses to CRF stimulation reported in the current study are understandable if CSF CRF concentrations are simply proportional to the activity of CRF-secreting hypothalamic neurons over time.
The pattern of association between AVP CSF and ACTH AUC follows simpler second-order kinetics but may nonetheless be more difficult to interpret. Forming a slightly U-shaped curve, ACTH AUC responses decrease as AVP CSF increases to its approximate mean value (3.14 pg/ml) in this sample. As AVP CSF continues to increase beyond this point, the ACTH AUC responses then begin to increase in parallel. As a secondary ACTH secretagogue, it seems intuitive that chronically elevated AVP secretion will be less likely than chronic CRF hypersecretion to produce a blunted pituitary ACTH response. Thus, the more consistent pattern of blunted ACTH response in association with CRF hypersecretion is not associated with AVP hypersecretion. The heightened ACTH responses among those patients with the highest concentrations of AVP may, in fact, reflect the capacity of AVP to facilitate CRF-induced pituitary activation even in the presence of CRF receptor downregulation. This interpretation is consistent with studies indicating that coadministration of a vasopressin analogue during the CRF stimulation test potentiates pituitary release of ACTH (Dickstein et al, 1996; Dinan et al, 1999; Scott et al, 1999) . This study's finding with respect to oCRF DOSE raises important considerations for future studies utilizing the CRF stimulation test. The study used weight-adjusted dosing (1 mg/kg) in an effort to ensure equivalent pituitary stimulation for patients of various body sizes. Examination of a scatterplot of oCRF DOSE vs ACTH AUC (data not shown) indicates that this strategy was successful up to a dose of approximately 100 mg (ie patient body weight of 100 kg). At doses over 100 mg, ACTH AUC increases in an exponential manner with increasing dose. The weight adjustment of oCRF doses may not, therefore, reliably equalize pituitary stimulation for patients weighing more than 100 kg.
This study has several limitations. First, the study sample is limited to adult women of reproductive age. The findings, therefore, may not be replicable in men or women of other ages. Second, CSF peptide concentrations were measured from samples obtained 24 h before the CRF stimulation test was performed. Although synchronizing both procedures at 4:00 pm on consecutive days eliminates potential confounding by circadian fluctuations in CRF secretion and HPA axis activity (Motomatsu et al, 1984; Watabe et al, 1987; Salata et al, 1988; Geracioti et al, 1992; Kling et al, 1994; Kellner et al, 1995; Keenan et al, 2001) , it is not certain that CSF peptide concentrations are constant from one day to the next. Furthermore, the model produced in this study comprised of afternoon samples may not accurately depict neuroendocrine function at other times in the diurnal cycle. For example, a previous study comparing morning vs evening ACTH responses to AVP stimulation (Salata et al, 1988) suggests that a more pronounced positive correlation between CSF AVP concentrations and pituitary responses to CRF administration may have been observed if the clinical procedures had been conducted in the morning. Third, the study did not include an assessment of HPA axis counter-regulatory mechanisms. Although the intent of the present study was to clarify the relationship between CRF and AVP activity within the CNS and pituitary corticotroph activity, this tightly coupled relationship is nevertheless subject to complex modulatory influences of feedback and feedforward mechanisms at numerous levels within the HPA axis. These regulatory mechanisms are important considerations when interpreting CRF stimulation results as indicated by the alterations in pituitary response to CRF caused by pretreatment with metyrapone (von Bardeleben et al, 1988; Lisansky et al, 1989; Young et al, 1995) or dexamethasone (Deuschle et al, 1998; Modell et al, 1998; Rybakowski and Twardowska, 1999) .
Future studies should further clarify the CNS implications of the results provided by the CRF stimulation test by linking this test not only with CSF studies but also with functional neuroimaging studies and indices of the magnitude of HPA axis feedback activity such as the dexamethasone suppression test or dexamethasone-CRF stimulation test. Studies coupled with tests of feedback activity should not be expected to provide monolithic answers that uniformly apply to all stress-related disorders. For example, it is increasingly clear that survivors of trauma frequently exhibit a dissociation of central CRF hyperactivity and adrenal dysfunction that is not witnessed in nontraumatized individuals with depression (Heim et al, 2000 (Heim et al, , 2001 . Such pathophysiological subtleties will be increasingly important as secondary mechanisms such as negative feedback are incorporated into the model.
Studies linking the CRF stimulation test with functional neuroimaging techniques are currently being planned. As suitable radioligands for binding sites for CRF, AVP, cortisol, and other neuroregulators are developed, coordinated neuroendocrine/neuroimaging batteries will provide minimally invasive means that potentially offer an incremental advance beyond CSF studies. Since the source of CSF CRF remains obscure, functional imaging techniques utilizing radioligands for CRF receptors and other neurohormone binding sites may remedy this shortcoming of CSF studies by delineating region-specific alterations in the density and binding affinities of such CNS-binding sites. When coupled with peripheral neuroendocrine assays including the CRF stimulation test, such imaging studies will likely further elucidate the relationship between peripheral HPA axis function and central neuronal CRF activity, thereby clarifying the conclusions regarding CNS function that can be drawn from neuroendocrine window strategies including the CRF stimulation test.
